 VANCOUVER and HOUSTON , March 31, 2020 CNW - ESSA Pharma Inc. ESSA, or the Company NASDAQ: EPIX, TSX-V: EPI, a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New Drug IND application to the U.S. Food and Drug Administration FDA to evaluate its lead clinical candidate, EPI-7386, in a Phase 1 clinical study for the treatment of patients with metastatic castration-resistant prostate cancer mCRPC. The Company also provided a business update as the COVID-19 situation rapidly evolves. 